biotech

Australia's favourite long-term growth story and biotech darling CSL (ASX:CSL) has reported its full-year results, with net profit after tax up 10% to approximately...

The healthcare space stands out given it serves a noble cause: firms are looking to increase standards of living for people everywhere. Australia is fortunate to have...

Little is more exciting than a speccy healthcare stock (The possibility of rapid price appreciation is probably only rivalled only by a good mining micro-cap). As it...

Earlier in the year, we found that Australia's best performing sectors of the past decade were healthcare and technology. They are both fan favourites given their...

The IIR Pharma & Biotech Index increased slightly in March, up 1.3%. The index has performed strongly since the lows resulting from the pandemic, up 67.4% over the...

A look at the performance of the pharmaceutical and biotech sector over the month of February, along with the companies providing exposure to in vitro diagnostics....

Investing in biotech is often seen as binary: you either win big or lose everything. The success of CSL has been well chronicled, however, is it possible to...

Dr Craig Collie of Regal Funds Management joins David on this episode of Inside the Rope to discuss his career to date, starting as a medical doctor in...

Healthcare, like technology, is about innovation. In recent years, scientists have developed a range of new tools to treat a wide range of health problems. These can...

After extensive research (detailed below) we believe Invex Therapeutics (IXC AU) will pass its upcoming phase 2 trial in Idiopathic Intracranial Hypertension (IIH)...